<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03973333</url>
  </required_header>
  <id_info>
    <org_study_id>IMC-C103C-101</org_study_id>
    <nct_id>NCT03973333</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab</brief_title>
  <official_title>A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A*0201-positive Patients With Advanced MAGE-A4-positive Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunocore Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunocore Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      IMC-C103C is an immune mobilizing T cell receptor against cancer (ImmTAC Â®) designed for the
      treatment of cancers positive for the tumor-associated antigen MAGE-A4. This is a
      first-in-human trial designed to evaluate the safety and efficacy of IMC-C103C in adult
      patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for
      MAGE-A4.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The IMC-C103C-101 Phase 1/2 study will be evaluated in patients with metastatic/unresectable
      tumors which include select Advanced Solid Tumors and will be conducted in two phases.

        1. To identify the MTD and/or RP2D of IMC-C103C as a single agent administered Q1W (Arm A1)
           and administered Q1W in combination with Q3W atezolizumab (Arm A2).

        2. To assess the preliminary anti-tumor activity of IMC C103C in one or more selected
           indications, as a single agent administered Q1W (Arm B1) and administered Q1W in
           combination with Q3W atezolizumab (Arm B2).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Sequential from arm A1 to A2: B1 can be opened after A1, which will run parallel with A2 and B2 can be opened after A2</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Incidence of dose-limiting toxicities (DLT)</measure>
    <time_frame>From first dose to DLT period (21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: incidence and severity of adverse events (AE)</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: changes in laboratory parameters</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Abnormalities will be classified according to NCI CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: changes in vital signs</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Abnormalities will be classified according to NCI CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: changes in electrocardiogram parameters</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>QTcF interval absolute values and changes from baseline will be summarized</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: dose interruptions, reductions, and discontinuations</measure>
    <time_frame>from first dose through last dose (anticipated for up to 12 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Best overall response (BOR)</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 2: incidence and severity of adverse events (AE)</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: changes in laboratory parameters</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Abnormalities will be classified according to NCI CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: changes in vital signs</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Abnormalities will be classified according to NCI CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: changes in electrocardiogram parameters</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>QTcF interval absolute values and changes from baseline will be summarized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: dose interruptions, reductions, and discontinuations</measure>
    <time_frame>from first dose through last dose (anticipated for up to 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Best overall response</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>2 weeks (IMC-C103C AUC will be assessed weekly for 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics The maximum observed plasma drug concentration after single dose administration (Cmax)</measure>
    <time_frame>2 weeks (IMC-C103C AUC will be assessed weekly for 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics The time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>2 weeks (IMC-C103C AUC will be assessed weekly for 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics The elimination half-life (t1/2)</measure>
    <time_frame>2 weeks (IMC-C103C AUC will be assessed weekly for 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity the incidence of anti-drug antibody formation</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lymphocyte counts over time</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum cytokines over time</measure>
    <time_frame>4 weeks</time_frame>
    <description>Cytokine / chemokine concentration data will be listed, summarized, or analyzed by treatment group for Phase 1 and separately for each Phase 2 cohort.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Select Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>IMC-C103C - Arm A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n= approximately 28 patients to establish the MTD/RP2D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMC-C103C and atezolizumab Arm A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=approximately 12 patients to establish the MTD/RP2D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMC-C103C - Arm B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be enrolled n=9-24 metastatic/unresectable tumors of interest patients treated at the RP2D of IMC-C103C to assess preliminary anti-tumor efficacy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMC-C103C and atezolizumab Arm B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be enrolled n=9-24 metastatic/unresectable tumors of interest patients treated at the RP2D of IMC-C103C to assess preliminary anti-tumor efficacy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMC-C103C</intervention_name>
    <description>Weekly IV infusions</description>
    <arm_group_label>IMC-C103C - Arm A1</arm_group_label>
    <arm_group_label>IMC-C103C - Arm B1</arm_group_label>
    <arm_group_label>IMC-C103C and atezolizumab Arm A2</arm_group_label>
    <arm_group_label>IMC-C103C and atezolizumab Arm B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Q3W</description>
    <arm_group_label>IMC-C103C and atezolizumab Arm A2</arm_group_label>
    <arm_group_label>IMC-C103C and atezolizumab Arm B2</arm_group_label>
    <other_name>TECENTRIQ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HLA-A*02:01 positive

          2. MAGE-A4 positive tumor

          3. ECOG PS 0 or 1

          4. Selected advanced solid tumors

          5. Relapsed from, refractory to, or intolerant of standard therapy

          6. Measurable disease per RECIST v1.1

          7. If applicable, must agree to use highly effective contraception

        Exclusion Criteria:

          1. Symptomatic or untreated central nervous system metastasis

          2. Inadequate washout from prior anticancer therapy

          3. Significant ongoing toxicity from prior anticancer treatment

          4. Impaired baseline organ function as evaluated by out-of-range laboratory values

          5. Clinically significant cardiac disease

          6. Active infection requiring systemic antibiotic therapy

          7. Known history of human immunodeficiency virus (HIV)

          8. Active hepatitis B virus (HBV) or hepatitis C virus (HCV)

          9. Ongoing treatment with systemic steroids or other immunosuppressive therapies

         10. Significant secondary malignancy

         11. Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammed Dar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Immunocore Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammed Dar, MD</last_name>
    <phone>484-534-5261</phone>
    <email>clinicaltrials@immunocore.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Angeles Clinic and Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodolfo Gutierrez, MD</last_name>
      <phone>310-231-2176</phone>
    </contact>
    <investigator>
      <last_name>Rodolfo Gutierrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medicine &amp; Biological Sciences</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randy F Sweis, MD</last_name>
      <phone>773-702-1152</phone>
    </contact>
    <investigator>
      <last_name>Randy F Sweis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Segal</last_name>
      <phone>646-888-4187</phone>
    </contact>
    <investigator>
      <last_name>Neil Segal, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diwakar Davar, MD</last_name>
      <phone>412-623-5950</phone>
    </contact>
    <contact_backup>
      <last_name>Diwakar Davar, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at Tennesse Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Johnson, MD</last_name>
      <phone>615-986-4366</phone>
    </contact>
    <investigator>
      <last_name>Melissa Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Blumenschein, MD</last_name>
      <phone>713-792-6363</phone>
    </contact>
    <investigator>
      <last_name>George Blumenschein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>November 7, 2019</last_update_submitted>
  <last_update_submitted_qc>November 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

